Taro Historical Income Statement

TARO Stock

USD 42.69 0.06 0.14%

Historical analysis of Taro Pharmaceutical income statement accounts such as EBIT of 20.4 M, Ebitda of 50 M, Cost Of Revenue of 340.4 M or Total Operating Expenses of 297.6 M can show how well Taro Pharmaceutical Industries performed in making a profits. Evaluating Taro Pharmaceutical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Taro Pharmaceutical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Taro Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Taro Pharmaceutical is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Taro Income Statement Analysis

Taro Pharmaceutical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Taro Pharmaceutical shareholders. The income statement also shows Taro investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Taro Pharmaceutical Income Statement Chart

Taro Pharmaceutical Industries Income Statement is one of the three primary financial statements used for reporting Taro's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Taro Pharmaceutical revenue and expense. Taro Pharmaceutical Income Statement primarily focuses on the company's revenues and expenses during a particular period.

At this time, Taro Pharmaceutical's Net Income is very stable compared to the past year. As of the 26th of May 2024, Minority Interest is likely to grow to 0.00, while Total Revenue is likely to drop about 365.8 M.

Total Revenue Gross Profit Other Operating Expenses Operating Income Reconciled Depreciation

Total Revenue

Total revenue comprises all receipts Taro Pharmaceutical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Taro Pharmaceutical Industries minus its cost of goods sold. It is profit before Taro Pharmaceutical operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Taro Pharmaceutical. It is also known as Taro Pharmaceutical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Taro Pharmaceutical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Taro Pharmaceutical Industries is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most accounts from Taro Pharmaceutical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Taro Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

	2021	2022	2023	2024 (projected)
Gross Profit	293.1M	268.3M	305.0M	238.5M
Total Revenue	561.3M	573.0M	629.2M	365.8M

Gross Profit Total Revenue

Taro Pharmaceutical income statement Correlations

	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Income Tax Expense	Depreciation And Amortization	Net Income	Research Development	Interest Expense	Selling General Administrative	Minority Interest	Selling And Marketing Expenses	Discontinued Operations	Net Income From Continuing Ops	Tax Provision	Extraordinary Items	Interest Income	Net Interest Income	Reconciled Depreciation
Total Revenue		0.94	0.25	0.67	0.66	0.67	0.24	0.25	0.68	0.1	0.82	0.09	0.65	0.86	0.24	0.7	0.5	-0.26	-0.18	0.36	0.29	0.27	0.06	0.02	-0.18
Gross Profit	0.94		0.01	0.73	0.72	0.72	-0.02	0.04	0.82	0.18	0.93	-0.14	0.79	0.72	0.39	0.61	0.6	-0.45	-0.2	0.57	0.53	0.11	0.09	-0.07	-0.45
Other Operating Expenses	0.25	0.01		-0.22	-0.22	-0.19	0.99	0.98	-0.17	0.01	-0.13	0.87	-0.17	0.5	-0.7	0.57	-0.13	0.82	-0.09	-0.52	-0.75	0.51	-0.24	0.17	0.75
Operating Income	0.67	0.73	-0.22		0.99	0.99	-0.18	-0.26	0.31	-0.5	0.6	-0.25	0.27	0.54	0.65	0.15	0.09	-0.6	-0.12	0.15	0.38	0.1	0.14	-0.07	-0.52
Ebit	0.66	0.72	-0.22	0.99		1.0	-0.18	-0.26	0.29	-0.51	0.59	-0.25	0.24	0.53	0.67	0.14	0.06	-0.6	-0.06	0.13	0.38	0.09	0.15	-0.09	-0.53
Ebitda	0.67	0.72	-0.19	0.99	1.0		-0.15	-0.23	0.28	-0.52	0.58	-0.22	0.23	0.54	0.64	0.16	0.05	-0.58	-0.06	0.11	0.35	0.11	0.14	-0.1	-0.5
Cost Of Revenue	0.24	-0.02	0.99	-0.18	-0.18	-0.15		0.93	-0.23	-0.08	-0.17	0.85	-0.24	0.51	-0.63	0.49	-0.18	0.78	-0.07	-0.59	-0.78	0.54	-0.26	0.22	0.74
Total Operating Expenses	0.25	0.04	0.98	-0.26	-0.26	-0.23	0.93		-0.09	0.11	-0.09	0.87	-0.08	0.47	-0.77	0.63	-0.08	0.84	-0.11	-0.42	-0.68	0.46	-0.2	0.11	0.73
Income Before Tax	0.68	0.82	-0.17	0.31	0.29	0.28	-0.23	-0.09		0.67	0.9	-0.34	1.0	0.39	0.31	0.51	0.87	-0.46	-0.22	0.89	0.72	-0.1	0.05	-0.06	-0.54
Total Other Income Expense Net	0.1	0.18	0.01	-0.5	-0.51	-0.52	-0.08	0.11	0.67		0.35	-0.12	0.7	-0.07	-0.23	0.34	0.72	0.05	-0.11	0.7	0.37	-0.18	-0.06	0.0	-0.08
Income Tax Expense	0.82	0.93	-0.13	0.6	0.59	0.58	-0.17	-0.09	0.9	0.35		-0.32	0.87	0.63	0.46	0.52	0.76	-0.55	-0.22	0.7	0.69	0.02	0.12	0.04	-0.59
Depreciation And Amortization	0.09	-0.14	0.87	-0.25	-0.25	-0.22	0.85	0.87	-0.34	-0.12	-0.32		-0.34	0.27	-0.73	0.52	-0.41	0.79	-0.04	-0.59	-0.74	0.33	-0.33	-0.11	0.75
Net Income	0.65	0.79	-0.17	0.27	0.24	0.23	-0.24	-0.08	1.0	0.7	0.87	-0.34		0.35	0.28	0.5	0.87	-0.43	-0.21	0.91	0.72	-0.11	0.04	-0.07	-0.53
Research Development	0.86	0.72	0.5	0.54	0.53	0.54	0.51	0.47	0.39	-0.07	0.63	0.27	0.35		0.07	0.58	0.39	0.02	-0.16	-0.02	-0.09	0.61	-0.03	0.23	0.1
Interest Expense	0.24	0.39	-0.7	0.65	0.67	0.64	-0.63	-0.77	0.31	-0.23	0.46	-0.73	0.28	0.07		-0.35	0.21	-0.9	0.02	0.38	0.63	-0.21	0.01	-0.07	-0.79
Selling General Administrative	0.7	0.61	0.57	0.15	0.14	0.16	0.49	0.63	0.51	0.34	0.52	0.52	0.5	0.58	-0.35		0.34	0.19	-0.17	0.23	0.06	0.13	0.04	-0.01	0.14
Minority Interest	0.5	0.6	-0.13	0.09	0.06	0.05	-0.18	-0.08	0.87	0.72	0.76	-0.41	0.87	0.39	0.21	0.34		-0.36	-0.19	0.78	0.58	0.14	0.13	0.27	-0.42
Selling And Marketing Expenses	-0.26	-0.45	0.82	-0.6	-0.6	-0.58	0.78	0.84	-0.46	0.05	-0.55	0.79	-0.43	0.02	-0.9	0.19	-0.36		-0.03	-0.6	-0.86	0.34	-0.23	0.04	0.9
Discontinued Operations	-0.18	-0.2	-0.09	-0.12	-0.06	-0.06	-0.07	-0.11	-0.22	-0.11	-0.22	-0.04	-0.21	-0.16	0.02	-0.17	-0.19	-0.03		-0.14	-0.06	0.35	0.0	0.1	0.03
Net Income From Continuing Ops	0.36	0.57	-0.52	0.15	0.13	0.11	-0.59	-0.42	0.89	0.7	0.7	-0.59	0.91	-0.02	0.38	0.23	0.78	-0.6	-0.14		0.88	-0.36	0.12	-0.16	-0.67
Tax Provision	0.29	0.53	-0.75	0.38	0.38	0.35	-0.78	-0.68	0.72	0.37	0.69	-0.74	0.72	-0.09	0.63	0.06	0.58	-0.86	-0.06	0.88		-0.48	0.26	-0.16	-0.88
Extraordinary Items	0.27	0.11	0.51	0.1	0.09	0.11	0.54	0.46	-0.1	-0.18	0.02	0.33	-0.11	0.61	-0.21	0.13	0.14	0.34	0.35	-0.36	-0.48		-0.2	0.36	0.4
Interest Income	0.06	0.09	-0.24	0.14	0.15	0.14	-0.26	-0.2	0.05	-0.06	0.12	-0.33	0.04	-0.03	0.01	0.04	0.13	-0.23	0.0	0.12	0.26	-0.2		0.55	-0.17
Net Interest Income	0.02	-0.07	0.17	-0.07	-0.09	-0.1	0.22	0.11	-0.06	0.0	0.04	-0.11	-0.07	0.23	-0.07	-0.01	0.27	0.04	0.1	-0.16	-0.16	0.36	0.55		0.11
Reconciled Depreciation	-0.18	-0.45	0.75	-0.52	-0.53	-0.5	0.74	0.73	-0.54	-0.08	-0.59	0.75	-0.53	0.1	-0.79	0.14	-0.42	0.9	0.03	-0.67	-0.88	0.4	-0.17	0.11

Click cells to compare fundamentals

Taro Pharmaceutical Account Relationship Matchups

Taro Pharmaceutical income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Revenue	644.8M	549.0M	561.3M	573.0M	629.2M	365.8M
Gross Profit	399.7M	296.7M	293.1M	268.3M	305.0M	238.5M
Other Operating Expenses	398.2M	403.8M	436.4M	555.2M	607.7M	638.1M
Operating Income	246.5M	704.4M	184.4M	17.7M	21.5M	20.4M
Ebit	246.5M	704.4M	184.4M	17.7M	21.5M	20.4M
Ebitda	253.1M	728.1M	210.3M	52.7M	52.6M	50.0M
Cost Of Revenue	245.0M	252.3M	268.2M	304.6M	324.2M	340.4M
Total Operating Expenses	153.2M	151.5M	168.2M	250.6M	283.5M	297.6M
Income Before Tax	298.0M	(391.1M)	77.9M	38.2M	82.7M	113.5M
Total Other Income Expense Net	51.5M	(1.1B)	(106.5M)	20.5M	61.2M	64.2M
Income Tax Expense	53.5M	9.7M	19.6M	12.8M	28.8M	24.2M
Depreciation And Amortization	6.5M	23.7M	25.9M	34.9M	31.1M	32.6M
Net Income	244.2M	(400.7M)	58.3M	25.4M	53.9M	91.1M
Research Development	59.8M	60.2M	54.5M	52.2M	64.5M	45.9M
Interest Expense	725K	1.4M	1.7M	(17.7M)	(15.9M)	(15.1M)
Selling General Administrative	56.8M	52.8M	57.1M	85.1M	97.8M	83.4M
Net Income Applicable To Common Shares	281.8M	244.2M	(386.7M)	58.3M	67.0M	63.7M
Minority Interest	5.2M	5.6M	5.9M	(8.2M)	(904K)	0.0
Selling And Marketing Expenses	36.7M	38.5M	56.6M	113.3M	130.3M	136.8M
Net Income From Continuing Ops	244.6M	(400.7M)	58.3M	25.4M	22.9M	21.8M
Tax Provision	53.5M	9.7M	19.6M	12.8M	11.5M	10.9M
Interest Income	22.7M	20.2M	8.2M	20.9M	18.8M	14.6M
Net Interest Income	33.6M	20.2M	8.2M	20.9M	18.8M	17.2M
Reconciled Depreciation	21.4M	23.7M	25.9M	32.1M	36.9M	25.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Taro Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taro Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taro Pharmaceutical Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taro Pharmaceutical Industries Stock:

How To Invest In Taro

Details

Is Taro Stock a good investment?

Details

What is Taro Pharmaceutical's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Taro Stock analysis

When running Taro Pharmaceutical's price analysis, check to measure Taro Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taro Pharmaceutical is operating at the current time. Most of Taro Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Taro Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taro Pharmaceutical's price. Additionally, you may evaluate how the addition of Taro Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Global Correlations Find global opportunities by holding instruments from different markets
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets

Is Taro Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taro Pharmaceutical. If investors know Taro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taro Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.181

Earnings Share

1.43

Revenue Per Share

16.74

Quarterly Revenue Growth

0.125

Return On Assets

0.0021

The market value of Taro Pharmaceutical is measured differently than its book value, which is the value of Taro that is recorded on the company's balance sheet. Investors also form their own opinion of Taro Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Taro Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taro Pharmaceutical's market value can be influenced by many factors that don't directly affect Taro Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Taro Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taro Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taro Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Taro Historical Income Statement

About Taro Income Statement Analysis

Taro Pharmaceutical Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Operating Income

Taro Pharmaceutical income statement Correlations

Taro Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Taro Pharmaceutical income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Taro Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Cost Of Revenue	+ 0.99	Other Operating Expenses
Ebit	+ 0.99	Operating Income
Ebitda	+ 0.99	Operating Income
Total Operating Expenses	+ 0.98	Other Operating Expenses

Selling And Marketing Expenses	- 0.9	Interest Expense
Reconciled Depreciation	- 0.88	Tax Provision
Tax Provision	- 0.86	Selling And Marketing Expenses
Reconciled Depreciation	- 0.79	Interest Expense
Tax Provision	- 0.78	Cost Of Revenue
Interest Expense	- 0.77	Total Operating Expenses